Clinical Trial

A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 16, 2025 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase 1/1b, open-label, first in human study of CPI-818, an oral interleukin-2-inducible tyrosine kinase (ITK) inhibitor for the treatment of relapsed/refractory (R/R) T-cell lymphoma.. This trial will study the safety, tolerability, and anti-tumor activity of CPI-818 as a single drug.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2019-05-14; most recent amendment 2025-04-14.
Status change: Recruiting → Active, Not Recruiting 2024-03-19
Trial Details
NCT Number NCT03952078
Lead Sponsor Corvus Pharmaceuticals, Inc.
Conditions T-cell Lymphoma
Enrollment 151 participants
Start Date 2019-05-03
Primary Completion 2026-04-30 (estimated)
Study Completion 2026-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-16